Pulmocide presented two posters at the recent 8th Advances Against Aspergillosis Conference, held February 1-3, 2018 in Lisbon, Portugal. There are as follow
A full copy of the scientific posters can be downloaded here:
PC945 shows a higher barrier than itraconazole to induction of Aspergillus fumigatus resistant mutants
PC945 is a novel inhaled triazole, which is now undergoing clinical phase testing. We investigated the experimental evolution of resistance to PC945 in A. fumigatus, by repeated exposure, and compared the observed kinetics with those of itraconazole.
Anti-fungal activities of PC1244, a novel inhaled triazole, on Aspergillus fumigatus strains with cyp51A mutations
presented by Pulmocide, V. P. Chest Institute (University of Delhi) and Center of Expertise in Mycology Radboudumc/Canisius-Wilhelmina Ziekenhuis (Netherlands)
PC1244 is a novel potent and long acting antifungal triazole designed for inhalation treatment of pulmonary aspergillosis and other difficult to treat fungi. In this study the antifungal activities of PC1244 were assessed by performing susceptibility testing against well-characterized azole-resistant Aspergillus fumigatus isolates.